Since the first transcatheter aortic valve implantation (TAVI) this method has spread out widely. Originally, this method was indicated for inoperable and high-risk patients; nowadays it has FDA approval even for low-risk patients.
As any invasive procedure, TAVI is also associated with complications, including prosthetic valve endocarditis (TAVI-IE). The incidence of TAVI-IE is reported to be 0.2-3.4 % and its mortality up to 67 % at two years after confirmation of the diagnosis.
The aim of this article is to review current knowledge on this serious complication.